6533b855fe1ef96bd12b08fa

RESEARCH PRODUCT

The use of same in chemotherapy-induced liver injury

Daniele SantiniG. ToniniAntonio RussoA. TerenzioF. VoriniAntonio GalvanoBruno VincenziUmberto Vespasiani-gentilucciRaffaele Antonelli-incalzi

subject

medicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsDrug-induced liver injurySettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineCholestasisChemotherapy inducedInternal medicineNeoplasmsmedicineAnimalsHumansChemotherapyLiver injuryChemotherapyS-adenosylmethioninebusiness.industryHepatotoxicityHematologymedicine.diseaseOncologyCholestasi030220 oncology & carcinogenesisImmunohistochemistry030211 gastroenterology & hepatologyChemotherapy; Cholestasis; Drug-induced liver injury; Hepatotoxicity; S-adenosylmethionine; Hematology; OncologyLiver functionChemical and Drug Induced Liver InjuryComplicationbusiness

description

Drug-induced liver injury (DILI) remains the most common cause of acute liver failure in the Western world. Chemotherapy is one of the major class of drugs most frequently associated with idiosyncratic DILI. For this reason, patients who receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate and which drug doses should be modified. S-adenosylmethionine (SAMe) is an endogenous agent derived from methionine. Its supplementation is effective in the treatment of liver disease, in particular intrahepatic cholestasis (IHC). The target of this review is to analyze the mechanisms of hepatotoxicity of the principal anticancer agents and the role of SAMe in the prevention of this complication.

yearjournalcountryeditionlanguage
2018-01-01
10.1016/j.critrevonc.2018.06.019http://hdl.handle.net/10447/295512